Cardiac transplantation. Selection, immunosuppression, and survival.
Cardiac transplantation has evolved from an experiment to an accepted therapy for severe heart failure. Increasing competition for donor organs mandates a greater emphasis on selection and timing for transplantation and paradoxically forces more reliance on aggressive medical therapy for all patients after evaluation. The growth of recipient and donor pools may enhance the opportunity for assessing histocompatibility, for which distinguishing between autoantibodies and human leukocyte antigen-determined reactivity is important, and some general nonresponders may be detected. Therapy with cyclosporine has improved the outcome after transplantation, but further refinement is needed, perhaps with pharmacologic synergy, to minimize nephrotoxicity and maximize specific immunosuppression. Survival is more than 80% at 1 year, after which the incidence of acute rejection and infection declines and accelerated atherosclerosis becomes prominent. Although resuming employment is not always possible, the overall quality of life is excellent after cardiac transplantation.
Stevenson
L W
LW
Laks
H
H
Terasaki
P I
PI
Kahan
B D
BD
Drinkwater
D C
DC
D003524:Cyclosporins / Q000627:therapeutic use; D006331:Heart Diseases / Q000401:mortality* / Q000601:surgery; D016027:Heart Transplantation; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy
D003524:Cyclosporins